Protective effect on AMP airway responsiveness after a single dose of fluticasone Source: Eur Respir J 2004; 24 : 711-712 Year: 2004
Protective effect of inhaled glucocorticosteroids on COPD model. Source: Virtual Congress 2020 – Mechanistic insight into lung injury and repair Year: 2020
Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001
Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol Source: Eur Respir J 2001; 17: 368-373 Year: 2001
The bronchoprotective effects of levocetirizine on adenosine monophosphate challenge in patients with atopic asthma Source: Eur Respir J 2004; 24: Suppl. 48, 220s Year: 2004
Mechanism of protective effect of inhaled budesonide on airway response to ozone (O3) exposure Source: Eur Respir J 2004; 24: Suppl. 48, 364s Year: 2004
The concept study: comparative influence of two treatment strategies on airway response to AMP Source: Annual Congress 2005 - Combination therapy for asthma. Which, why and how? Year: 2005
Effect of oral prednisolone on the bronchoprotective effect of formoterol in patients with persistent asthma Source: Eur Respir J 2001; 17: 374-379 Year: 2001
Protective effect of inhaled glucocorticosteroid and long-acting beta2-agonist combination on COPD model Source: Virtual Congress 2021 – Developments in biomarkers and treatment strategies for chronic lung diseases Year: 2021
RPL554, an inhaled PDE3/4 inhibitor, causes comparable bronchodilation to high dose nebulised salbutamol in asthmatics with fewer systemic effects Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016
Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination vs. high doses of ICS: efficacy and safety in patients (pts) with uncontrolled occupational asthma Source: International Congress 2017 – Techniques to treat asthma Year: 2017
Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs. ICS alone Source: Eur Respir J 2004; 24: Suppl. 48, 308s Year: 2004
Anti-inflammatory effect of montelukast (ML) and inhaled steroids (ICS) on clinical parameters and serum levels of NO in asthmatic children Source: Eur Respir J 2003; 22: Suppl. 45, 132s Year: 2003
Effects of a single inhaled budesonide/formoterol dose on glucocorticoid receptor activity in sputum of COPD patients Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016
Tolerance to the protective effect of salmeterol on allergen challenge in mild untreated asthmatics and in moderate asthmatics on inhaled corticosteroid treatment Source: Eur Respir J 2001; 18: Suppl. 33, 103s Year: 2001
Dose response to budesonide using adenosine monophosphate (AMP) bronchial challenge: assessment of two dry powder inhalers Source: Eur Respir J 2002; 20: Suppl. 38, 502s Year: 2002
Effect of IgE sensitization and allergen exposure on exhaled NO during inhaled corticosteroid (ICS) treatment in patients with asthma Source: Annual Congress 2007 - Primary care respiratory problems Year: 2007
Acute effects of higher than customary doses of salmeterol (SM) and salbutamol (SB) in patients with acute exacerbation of COPD Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001
Effect of switching from high-dose inhaled corticosteroid (ICS) to low-dose ICS plus an inhaled long-acting β2 -agonist on asthma control, airway inflammation and remodeling, and gene expression in airway epithelial cells Source: Eur Respir J 2003; 22: Suppl. 45, 35s Year: 2003
Acute asthma treatment: comparison of formoterol and salbutamol given in cumulative doses in children Source: Eur Respir J 2001; 18: Suppl. 33, 122s Year: 2001